Protein C inhibitor as a biomarker for prostate cancer
US8440409B2 · kind B2 · utility
4Cited by
3References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 19, 2006 |
| Grant date | May 14, 2013 |
| Priority date | — |
| Expiry date | Oct 2, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/8121
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides a protein-based biomarker, Protein C Inhibitor (PCI) that is useful in qualifying prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as prostate cancer or non-prostate cancer. The biomarker can be detected by SELDI mass spectrometry.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.